The age at which psoriasis first appears can be an important predictor for the transition to psoriatic arthritis.Read More
Watch as Juliette Yedimenko, MD, discusses a case in which a dermatomyositis flare led to the discovery of a müllerian carcinoma.
Despite 15 years of experience with tumor necrosis factor -α inhibitor (TNFI) -induced psoriasis, our understanding of its pathogenesis remains incomplete. A recent case-control study identified risk factors and triggers associated with the onset of this condition.
Ethnicity influences the epidemiology and clinical phenotype of sarcoidosis; however, data on clinical manifestations of sarcoidosis in Asians are relatively limited. In this article, rheumatologist Patompong Ungprasert, MD, discusses the results of a 14-year, single center study from Thailand.
Data analysis reveals that Black patients with systemic lupus erythematosus (SLE) are 5x more likely to use chronic glucocorticoids than white patients. Healthcare access may play a role.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Diagnosis of fibroblastic rheumatism is based on characteristic clinical findings in combination with histopathological findings. This case study illustrates the differential diagnosis, and reviews imaging and laboratory findings.
Co-management clinics yield improved patient outcomes and increased opportunities for research and education. In this article, rheumatologist Elaine Husni, MD, MPH, and dermatologist Anthony Fernandez, MD, PhD, discuss their new shared clinic.
Tumor necrosis factor-α inhibitors (TNFis) have transformed care for rheumatoid arthritis and other autoimmune diseases, but they also are associated with higher risks of serious and opportunistic infections than traditional disease-modifying antirheumatic drugs. In this article, Cassandra Calabrese, DO, discusses balancing the benefits of biologic therapies with the risks of infection.
Two female patients with anti-PM-Scl antibody-associated systemic sclerosis developed progressive proximal myopathy. Both patients had profound muscle weakness that was refractory to treatment with glucocorticoids with or without other oral immunosuppressants. In this article, rheumatologist Souyma Chatterjee, MD, shares two cases of anti-PM-Scl antibody-associated scleromyositis in which a muscle biopsy unexpectedly showed features of sporadic inclusion body myositis.
Is checkpoint inhibitor-related polymyalgia rheumatica (PMR) distinct from the classic rheumatic disease, or does it represent new clinical variants with potentially different pathogenesis, clinical course and treatment responsiveness? Rheumatologist/immunologist Cassandra Calabrese, DO, discusses her research, which identified clinical features that are unusual in idiopathic PMR.
A 58‐year‐old female with an 18‐year history of limited cutaneous systemic sclerosis presents with severe pain and ulceration affecting the tips of her fingers. On examination, there was evidence of auto‐amputation of some of her distal phalanges and ulceration of the overlying skin. What’s the diagnosis?